Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for RenovoRx, Inc. (RNXT : NSDQ)

• Company Description    RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $0.88 Daily Weekly Monthly 20 Day Moving Average: 291,998 shares Shares Outstanding: 45.10 (millions) Market Capitalization: $39.75 (millions) Beta: 1.00 52 Week High: $1.45 52 Week Low: $0.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.06% -6.84% 12 Week 1.91% -5.79% Year To Date 4.93% -3.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2570 West El Camino Real Suite 640 - Mountain View,CA 94040 USA ph: 650-284-4433 fax: 650-397-4433 renovorx@kcsa.com http://www.renovorx.com

• General Corporate Information    Officers Shaun R. Bagai - Chief Executive Officer; Director Ramtin Agah - Executive Chairman and Chief Medical Officer Mark Voll - Chief Financial Officer Laurence J. Marton - Director Una S. Ryan - Director Peer Information RenovoRx, Inc. (CORR.) RenovoRx, Inc. (RSPI) RenovoRx, Inc. (CGXP) RenovoRx, Inc. (BGEN) RenovoRx, Inc. (GTBP) RenovoRx, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75989R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 45.10 Most Recent Split Date: (:1) Beta: 1.00 Market Capitalization: $39.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.53 Price/Cash Flow: - Price / Sales: 26.70 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 185.79% vs. Previous Quarter: 136.55% ROE 03/31/26 - -135.03 12/31/25 - -119.77 09/30/25 - -122.19 ROA 03/31/26 - -101.92 12/31/25 - -91.25 09/30/25 - -90.69 Current Ratio 03/31/26 - 7.15 12/31/25 - 4.02 09/30/25 - 5.83 Quick Ratio 03/31/26 - 6.95 12/31/25 - 3.93 09/30/25 - 5.68 Operating Margin 03/31/26 - -802.69 12/31/25 - -994.48 09/30/25 - -1,196.66 Net Margin 03/31/26 - -823.98 12/31/25 - -994.48 09/30/25 - -1,196.66 Pre-Tax Margin 03/31/26 - -823.98 12/31/25 - -994.48 09/30/25 - -1,196.66 Book Value 03/31/26 - 0.25 12/31/25 - 0.15 09/30/25 - 0.22 Inventory Turnover 03/31/26 - 1.51 12/31/25 - 2.84 09/30/25 - 4.40 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©